Press & Downloads

Croma-Pharma: Further strengthening its portfolio with PhilArt biostimulators

Croma-Pharma is expanding its management team

Croma-Pharma completed the decentralized procedure for its botulinum toxin to treat glabellar (frown) lines

Croma-Pharma Announces 9-Country Licensing Agreement with Crescita Therapeutics for Pliaglis®

Croma-Pharma presents new cosmetic skincare brand "Croma farewell™" for common skin conditions

Croma establishes new Joint Venture in China

Croma-Pharma GmbH expands its portfolio introducing pure HA

Croma-Pharma announces submission for their botulinum toxin to treat glabellar (frown) lines to the German authority BfArM

BVI forges strategic partnership with Croma-Pharma

Croma-Pharma supports Light for the World

Croma-Pharma GmbH establishes affiliate in UK

Croma-Pharma reveals new packaging design for the Arthrex ACP® double syringe system

Croma-Pharma GmbH expands its portfolio introducing elure

Croma-Pharma: "Made in Austria" - with minimally invasive aesthetic medicine (MIAM) becoming a global player

Leobendorf, March 2018 - Croma-Pharma GmbH, or Croma for short, is an international pharmaceutical company based in Leobendorf, Austria. For over 40 years, innovative drugs and medical devices for the fields of ophthalmology, orthopedics and aesthetic dermatology have been developed and produced. Thus, Croma has made important contributions to improving health and quality of life for four decades.